N@N

PolyMedix to Present at the Noble Financial Equity Conference

_{//health-fitness.news-articles.net/content/2011/ .. nt-at-the-noble-financial-equity-conference.html}
^{Published in Health and Fitness on Monday, May 16th 2011 at 4:05 GMT by Market Wire}  

RADNOR, Pa.--([ BUSINESS WIRE ])--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, will be presenting at the Noble Financial Capital Marketsa™ Seventh Annual Equity Conference. The Conference will take place May 16-17, 2011 at the Hard Rock Hotel in Hollywood, Florida.

Edward Smith, Vice President of Finance & CFO of PolyMedix will present on Tuesday, May 17, 2011 at 9:00 AM ET. The presentation will be webcast live and may be accessed on the Companya™s website at [ www.polymedix.com ] or by pasting the following link in your web browser [ http://noble.mediasite.com/mediasite/Viewer/?peid=54a9b821c5784214a501bc0fb72d47e11d ]. A replay will be available on both sites for 90 days following the event.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs for the treatment of serious infectious diseases and acute cardiovascular disorders. PolyMedix uses a rational drug design approach to create non-peptide, small-molecule drug candidates. PolyMedixa™s lead antibiotic compound, PMX-30063, is currently in a Phase 2 clinical trial for treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Staph, including MRSA. PMX-30063 is a small-molecule that mimics the mechanism of action of human host defense proteins, a mechanism that is distinct from currently approved antibiotic drugs and is intended to make bacterial resistance unlikely to develop. PolyMedixa™s lead heptagonist compound, PMX-60056, is in a Phase 2 clinical trial in patients undergoing PCI procedures. PMX-60056 is designed to reverse the anticoagulant activity of both heparin and low molecular weight heparins (LMWH). PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin and LMWH. In addition to its small molecule therapeutics, PolyMedix has polymeric formulations with the same mechanism of action as PMX-30063, PolyCides^®. PolyCides are intended for use in antimicrobial biomaterials applications as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit our website at [ www.polymedix.com ].

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedixa™s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as aanticipates,a abelieves,a ahopes,a aestimates,a alooks,a aexpects,a aplans,a aintends,a agoal,a apotential,a amay,a asuggest,a and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are PolyMedixa™s need for, and the availability of, substantial capital in the future to fund its operations and research and development, and the fact that PolyMedixa™s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedixa™s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.